April 12, 2023. ZURICH and CAMBRIDGE, Mass.– GlobeNewswire — Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the details of their presence at the American Association for Cancer Research (AACR) Annual Meeting 2023, which will be held April 14-19, 2023 in Orlando, Florida. The company will be presenting 8 scientific posters around their three research service platforms, TrueDiscovery™, TrueTarget™, and TrueSignature™, in collaboration with leading biopharma and academic researchers.
Biognosys’ team of scientific experts will also be exhibiting at booth #319. In addition to presenting their suite of research platforms and applications, the company will be unveiling and demonstrating for the first time their new Proteoverse data exploration tool.
“Our strong scientific presence with leading collaborators at the AACR Annual Meeting demonstrates the growing momentum of mass spectrometry-based proteomics in oncology biomarker research and drug development,” said Kristina Beeler, Ph.D., Chief Business Officer of Biognosys. “The launch of Proteoverse™ revolutionizes proteomics data analysis and marks a significant leap towards making proteomics even more accessible and actionable for researchers to identify novel biomarkers and drug targets – helping to continue this forward momentum.”
Biognosys’ strategic partner, Bruker, will be present at booth #1818 to present their proteomics ecosystem and imaging capabilities in oncology.
Biognosys’ innovative research services platforms provide industry-leading depth and quality in mass spectrometry data generation. Proteoverse enhances accessibility to this rich data and provides a wide range of intuitive and interactive data visualization and exploration features. Customers can quickly and easily extract valuable biological insights to advance their research by uncovering the most interesting analytes out of thousands of proteins, exploring their peptide-level structure, and examining their biological relevance.
The tool will be offered alongside Biognosys’ TrueDiscovery research service projects, first as an early-access version and eventually for all customers.
Posters will be available for downloading at biognosys.com/aacr23 by Wednesday, April 19th.
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced patented Data Independent Acquisition (DIA)-based protein quantification technology co-invented by tech pioneers at Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms.
The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.
The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.
TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.
The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio.
The Biognosys TrueSignature platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring.
Parallel Reaction Monitoring mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of up to 100 proteins.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel. The measurements are performed with unprecedented speed and throughput at Biognosys’ state-of-the-art facility, the world’s largest high-end GLP-certified and GCP-compliant mass spectrometry laboratory. For more information, visit truesignature.bio.
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
Head of Marketing and Communications
Phone +41 (0) 44 244 50 07